Sino Biopharmaceutical Limited is an investment holding company whose subsidiaries develop and commercialize pharmaceuticals, primarily in oncology, liver and cardiometabolic diseases, and respiratory and autoimmune conditions. The group's key products include anlotinib, benmelstobart, culmerciclib, rovadicitinib, and magnesium isoglycyrrhizinate, alongside a pipeline of antibody-drug conjugates, bispecific antibodies, and siRNA therapeutics. It operates R&D centers in Shanghai, Nanjing, Beijing, and Guangzhou, and serves markets in China and internationally, including the United States and Australia. In 2026, the company granted Sanofi an exclusive global license for rovadicitinib. The group also maintains a strategic partnership with China Resources Pharmaceutical Group.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage sbpgroup.com
Sector Healthcare IR page sbpgroup.com/investor-relations
Tags
oncology, antibody-drug conjugates, bispecific antibodies, sirna therapeutics, liver diseases, cardiometabolic diseases, respiratory diseases, autoimmune diseases, small molecules, protein degraders, Saitanxin, Culmerciclib, Hernexeos, Zongertinib, Putanning, Meloxicam, Anqixin, Recombinant Human Coagulation Factor VIIa, Focus V, Anlotinib, Andewei, Benmelstobart, Anxu, Rovadicitinib, Yilishu, Efbemalenograstim Alfa, Anboni, Unecritinib, Anluoqing, Envonalkib, Anfangning, Garsorasib, Anbeisi, Bevacizumab, Delituo, Rituximab, Saituo, Trastuzumab, Paletan, Pertuzumab, LM-302, LM-108, M701, TQB2868, TQB2102, TQB3019, Tianqing Ganmei, Magnesium Isoglycyrrhizinate, Lanifibranor, CPX101, Kylo-11, Kylo-12, Kylo-0603, TQC3721, Zhengda Tianqing, Sanofi
Press page —

Metrics

Valuation  
Market cap HK$ 100.23B
Market cap (USD) $ 12.773B
P/E 36.77
PEG 0.99
P/BV 1.77
P/S 2.53
P/OCF 8.15
P/FCF —
Dividend yield 2.2%
Turnover / mcap 0.20%
Returns  
ROE 12.5%
ROI 10.5%
ROIC 10.5%
Profit margin 16.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 37.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 18.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 31.834B 28.866B 26.199B 28.78B 26.861B 23.647B 24.234B 20.889B 14.819B 13.6B 11.834B 9.847B 7.82B 6.819B 4.761B 3.559B
Net profit 5.315B 3.5B 2.332B 2.544B 14.608B 2.771B 2.707B 9.046B 2.171B 1.644B 1.447B 1.204B 818.856M 729.513M 381.039M 493.798M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 5.76 3.42 3.19 — 4.81 6.28 4.8 4.65 13.35 — — — — — — —
Price performance 12m 0.72 0.08 — — -0.18 0.31 0 -0.66 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Sino Biopharmaceutical Limited (ticker 1177), listed in Hong Kong.

Company History

Date Change Detail
Jun 30, 2017 Reporting currency Its HK reports are in CNY instead of HKD from this period. Earlier figures are shown in CNY, converted at each period end's exchange rate.

ETFs Holding Sino Biopharmaceutical Limited

ETF Weight in ETF Shares Market value As of
MEMA 0.97% 175,000 $ 121.663K Aug 31, 2026
EMOP 0.48% 17,932,000 $ 10.084M Jun 30, 2026
TDI 0.38% 2,435,000 $ 1.369M Jun 30, 2026
DEHP 0.16% 912,000 $ 647.555K Nov 12, 2026
AVSE 0.13% 396,000 $ 276.147K Nov 16, 2026
AVEM 0.12% 46,694,500 $ 32.562M Nov 16, 2026
DFSE 0.10% 797,000 $ 565.9K Nov 12, 2026
REMG 0.07% 140,000 $ 78.721K Jun 30, 2026
NTSE 0.06% 66,000 $ 37.115K Jun 30, 2026
DFAE 0.05% 6,358,000 $ 4.514M Nov 12, 2026
DFEM 0.04% 5,359,000 $ 3.805M Nov 12, 2026
DFAX 0.02% 3,258,000 $ 2.313M Nov 12, 2026